Effect of non–phospholipid-based cationic and phospholipid-based anionic nanosized emulsions on skin retention and anti-inflammatory activity of celecoxib

References

• Sarkar DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv 2005;2:1–14.
   PubMedGoogle Scholar
• Capek I. Degradation of kinetically-stable o/w emulsions. Adv Colloid Interface Sci 2004;107:125–155.
   PubMed Web of Science ®Google Scholar
• He CX, He ZG, Gao JQ. Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs. Expert Opin Drug Deliv 2010;7:445–460.
   PubMed Web of Science ®Google Scholar
• Grigoriev DO, Miller R. Mono- and multilayer covered drops as carriers. Curr Opin Colloid Interface Sci 2009;14:48–59.
   Web of Science ®Google Scholar
• Hippalgaonkar K, Majumdar S, Kansara V. Injectable lipid emulsions-advancements, opportunities and challenges. AAPS PharmSciTech 2010;11:1526–1540.
   PubMed Web of Science ®Google Scholar
• Tamilvanan S. Formulation of multifunctional oil-in-water nanosized emulsions for active and passive targeting of drugs to otherwise inaccessible internal organs of the human body. Int J Pharm 2009;381:62–76.
   PubMed Web of Science ®Google Scholar
• Tamilvanan S. Oil-in-Water Nanosized Emulsions: Medical Applications. In: Gad SC, ed. Pharmaceutical Manufacturing Handbook. NJ, United States: John Wiley & Sons Publishers, Chap. 7.4, 2008:1329–1368.
   Google Scholar
• Rabinovich-Guilatt L, Couvreur P, Lambert G, Goldstein D, Benita S, Dubernet C. Extensive surface studies help to analyse zeta potential data: the case of cationic emulsions. Chem Phys Lipids 2004;131:1–13.
   PubMed Web of Science ®Google Scholar
• Tamilvanan S, Khoury K, Gilhar D, Benita S. Ocular delivery of cyclosporin A. I. Design and characterization of cyclosporin A-loaded positively-charged submicron emulsion. STP Pharm Sci 2001;11:421–426.
   Google Scholar
• Christensen D, Kirby D, Foged C, Agger EM, Andersen P, Perrie Y et al. alpha,alpha’-trehalose 6,6′-dibehenate in non-phospholipid-based liposomes enables direct interaction with trehalose, offering stability during freeze-drying. Biochim Biophys Acta 2008;1778:1365–1373.
   PubMed Web of Science ®Google Scholar
• Tamilvanan S, Kumar BA, Senthilkumar SR, Baskar R, Sekharan TR. Stability assessment of injectable castor oil-based nano-sized emulsion containing cationic droplets stabilized by poloxamer-chitosan emulsifier films. AAPS PharmSciTech 2010;11:904–909.
   PubMed Web of Science ®Google Scholar
• Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB et al. Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 2009;136:2127–2136.e1.
   Google Scholar
• Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM. Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford) 2007;46:135–140.
   PubMed Web of Science ®Google Scholar
• Gaurel A, Martel AM, Castaner J. Celecoxib, anti-inflammatory, cyclo-oxygenase-2 inhibitor. Drugs Future 1997;22:711–714.
   Google Scholar
• Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Celecoxib nanoemulsion: skin permeation mechanism and bioavailability assessment. J Drug Target 2008;16:733–740.
   PubMed Web of Science ®Google Scholar
• Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Design, development and evaluation of novel nanoemulsion formulations for transdermal potential of celecoxib. Acta Pharm 2007;57:315–332.
   PubMedGoogle Scholar
• Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. Enhanced anti-inflammatory effects of celecoxib from a transdermally applied nanoemulsion. Pharmazie 2009;64:258–259.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Ghosal SK, Moulik SP. Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion. Drug Dev Ind Pharm 2005;31:405–416.
   PubMed Web of Science ®Google Scholar
• Subramanian N, Ghosal SK, Moulik SP. Topical delivery of celecoxib using microemulsion. Acta Pol Pharm 2004;61:335–341.
   PubMedGoogle Scholar
• Karim A, Brugger AM, Gao P, Hassan F, Forbes JC. 2003. Use of a celecoxib composition for fast pain relief. US Patent No. 6,579,895 B2.
   Google Scholar
• Wang LX, He HB, Tang X, Shao RY, Chen DW. A less irritant norcantharidin lipid microspheres: Formulation and drug distribution. Int J Pharm 2006;323:161–167.
   PubMed Web of Science ®Google Scholar
• Férézou J, Nguyen TL, Leray C, Hajri T, Frey A, Cabaret Y et al. Lipid composition and structure of commercial parenteral emulsions. Biochim Biophys Acta 1994;1213:149–158.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Tang X, Li HY, Liu XL. A lipid microsphere vehicle for vinorelbine: Stability, safety and pharmacokinetics. Int J Pharm 2008;348:70–79.
   PubMed Web of Science ®Google Scholar
• Jalalizadeh H, Amini M, Ziaee V, Safa A, Farsam H, Shafiee A. Determination of celecoxib in human plasma by high-performance liquid chromatography. J Pharm Biomed Anal 2004;35:665–670.
   PubMed Web of Science ®Google Scholar
• Ghouchi Eskandar N, Simovic S, Prestidge CA. Nanoparticle coated submicron emulsions: sustained in-vitro release and improved dermal delivery of all-trans-retinol. Pharm Res 2009;26:1764–1775.
   PubMedGoogle Scholar
• Amselem S, Friedman D. Submicron emulsions as drug carriers for topical administration. In: Benita S. ed. Submicron emulsions in drug targeting and delivery. London: Harwood Academic, 1998: 5 3–73.
   Google Scholar
• Winter CA. Anti-inflammatory testing methods: Comparative evaluation of indomethacin and other agents. Int Symp Nonst Anti-inflamm Drugs 1965;82:190–202.
   Google Scholar
• Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123–133.
   PubMed Web of Science ®Google Scholar
• Levy MY, Benita S. Drug release from submicronized o/wemulsion: a new in vitro kinetic evaluation model. Int J Pharm 1990;66:29–37.
   Web of Science ®Google Scholar
• Santos Magalhaes NS, Cave G, Seiller M, Benita S. The stabilityand in vitro release kinetics of a clofibride emulsion. Int J Pharm 1991;76:225–237.
   Google Scholar
• Magenheim B, Levy MY, Benita S. A new in vitro technique forthe evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm 1993;94:115–123.
   Web of Science ®Google Scholar
• Washington C, Evans K. Release rate measurements of model hydrophobic solutes from submicron triglyceride emulsions. J Control Rel 1995;33:383–390.
   Web of Science ®Google Scholar
• Nishikawa M, Takakura Y, Hasida M. Biofate of fat emulsions. In: Benita S. ed. Submicron Emulsions in Drug Targeting and Delivery. London: Harwood Academic Publishers, 1998, pp. 99–118.
   Google Scholar
• Klang S, Benita S. Design and evaluation of submicron emulsions ascolloidal drug carriers for intravenous administration. In: Benita S, ed.Submicron Emulsions in Drug Targeting and Delivery. London: Harwood Academic Publishers, 1998, pp. 119–152.
   Google Scholar
• Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm 2009;73:107–114.
   PubMed Web of Science ®Google Scholar
• Tamilvanan S, Ajith Kumar B. Influence of acetazolamide loading on the (in vitro) performances of non-phospholipid-based cationic nanosized emulsion in comparison to phospholipid-based anionic and neutral-charged nanosized emulsions. Drug Dev Ind Pharm, In Press.
   Google Scholar
• Touitou E, Abed L. Effect of propylene glycol, azone and n-decylmethyl sulphoxide on skin permeation kinetics of 5-fluorouracil. Int J Pharm 1985;27:89–98.
   Web of Science ®Google Scholar
• Touitou E, Levi-Schaffer F, Dayan N, Alhaique F, Riccieri F. Modulation of caffeine skin delivery by carrier design: liposomes versus permeation enhancers. Int J Pharm 1994;103:131–136.
   Web of Science ®Google Scholar
• Lehman PA, Malany AM. Evidence for percutaneous absorption of isotretinoin from the photo-isomerization of topical tretinoin. J Invest Dermatol 1989;93:595–599.
   PubMed Web of Science ®Google Scholar
• Lehman PA, Slattery JT, Franz TJ. Percutaneous absorption of retinoids: influence of vehicle, light exposure, and dose. J Invest Dermatol 1988;91:56–61.
   PubMed Web of Science ®Google Scholar
• Touitou E, Meidan VM, Horwitz E. Methods for quantitative determination of drug localized in the skin. J Control Release 1998;56:7–21.
   PubMed Web of Science ®Google Scholar
• Higaki K, Amnuaikit C, Kimura T. Strategies for overcoming the stratum corneum: chemical and physical approaches. Am J Drug Deliv 2003;1:187–214.
   Google Scholar
• WilkersonVA. The chemistry of human epidermis II. The isoelectric point of the stratum corneum, hair, and nails as determined by electrophoresis. J Biol Chem 1935;112:329–335.
   Google Scholar
• Takeuchi Y, Yasukawa H, Yamaoka Y, Morimoto Y, Nakao S, Fukumori Y et al. Destabilization of whole skin lipid bio-liposomes induced by skin penetration enhancers and FT-IR/ATR (Fourier transform infrared/attenuated total reflection) analysis of stratum corneum lipids. Chem Pharm Bull 1992;40:484–487.
   PubMed Web of Science ®Google Scholar
• Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm 2008;357:295–304.
   PubMed Web of Science ®Google Scholar
• Lombardi Borgia S, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K et al. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release 2005;110:151–163.
   PubMed Web of Science ®Google Scholar
• Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H. Enhancement of topical delivery from biodegradable nanoparticles. Pharm Res 2004;21:1818–1825.
   PubMed Web of Science ®Google Scholar
• Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 2000;49:211–218.
   PubMed Web of Science ®Google Scholar
• Hadgraft J. Skin, the final frontier. Int J Pharm 2001;224:1–18.
   PubMed Web of Science ®Google Scholar
• Cho SH, Kim SY, Lee SI, Lee YM. Hydroxypropyl-ß-cyclodextrin inclusion complexes for transdermal delivery: preparation, inclusion properties, stability, and release behavior. J Ind Eng Chem 2006;12:50–59.
   Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54 Suppl 1:S131–S155.
   PubMed Web of Science ®Google Scholar
• Müller RH, Dingler A. The next generation after the liposomes: solid lipid nanoparticles as dermal carrier in cosmetics. Eurocosmetics 1998;7–8:19–26.
   Google Scholar
• Binks BP. Modern aspects of emulsion science. Cambridge, United Kingdom: The Royal Society of Chemistry, 1998.
   Google Scholar
• Müller RH, Dingler A. The next generation after the liposomes: solidlipid nanoparticles as dermal carrier in cosmetics. Eurocosmetics 1998;7-8:19–26.
   Google Scholar
• Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–177.
   PubMed Web of Science ®Google Scholar
• Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic anddermatological preparations. Adv Drug Deliv Rev 2002;54:S131–55.
   PubMed Web of Science ®Google Scholar
• Dingler A, Blum RP, Niehus H, Müller RH, Gohla S. Solid lipid nanoparticles (SLN/Lipopearls) – a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 1999;16:751–767.
   PubMed Web of Science ®Google Scholar